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Abstract
Multiple sclerosis (MS) is a chronic and often progressive, demyelinating disease of the central nervous system (CNS) white and
gray matter and the single most common cause of disability in young adults. Age is one of the factors most strongly influencing
the course of progression in MS. One of the hallmarks of aging is cellular senescence. The elimination of senescent cells with
senolytics has very recently been shown to delay age-related dysfunction in animal models for other neurological diseases. In this
review, the possible link between cellular senescence and the progression of MS is discussed, and the potential use of senolytics
as a treatment for progressive MS is explored. Currently, there is no cure for MS and there are limited treatment options to slow
the progression of MS. Current treatment is based on immunomodulatory approaches. Various cell types present in the CNS can
become senescent and thus potentially contribute to MS disease progression. We propose that, after cellular senescence has
indeed been shown to be directly implicated in disease progression, administration of senolytics should be tested as a potential
therapeutic approach for the treatment of progressive MS.
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PIGF Placental growth factor
PP-MS Primary progressive MS
PRDX Peroxiredoxin
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REST Repressor element 1-silencing
transcription factor





SASP Senescence-associated secretory phenotype
SCAP Senescent cell anti-apoptotic pathway
SCF Stem cell factor
SDF Stromal cell-derived factor
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Sirt6 Sirtuin 6
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sTNFR Soluble tumor necrosis factor receptor
TACI Transmembrane activator and calcium
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TGFβ Transforming growth factor β
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TNF-α Tumor necrosis factor α
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apoptosis-inducing ligand
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uPAR uPA receptor
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Introduction
Age is one of the most influential factors in MS progres-
sion [1, 2]. Several studies have shown that age affects
disease progression of MS independently of initial dis-
ease pattern, disease duration, and gender [2, 3]. Aging
can be defined as the time-dependent decline of function-
al capacity, which affects most living organisms [4]. The
nine hallmarks that are generally considered to contrib-
ute to the aging process are genomic instability, telomere
attrition, epigenetic alterations, loss of proteostasis,
deregulated nutrient sensing, mitochondrial dysfunction,
cellular senescence, stem cell exhaustion, and altered in-
tercellular communication. These hallmarks are intercon-
nected and contribute to aging and the development of
age-related diseases [4]. Cellular senescence, one of the
major hallmarks of the aging process, is a phenomenon
by which cells go into irreversible growth arrest and
become resistant to apoptosis. The number of senescent
cells present in the human body increases with aging,
which can have deleterious effects on the tissue micro-
environment [5].
Several drugs have been approved for the treatment of
relapsing-remitting phase of MS. Unfortunately, these
drugs show little or no therapeutic effect in progressive
MS. The first drug which was approved for the treatment
of relapsing-remitting MS (RR-MS) was interferon-β1
(IFN-β1). To date, there are 13 FDA-approved drugs
available for treatment of RR-MS. In general, these
drugs act mainly by suppressing or altering the immune
system. Also, these drugs have side effects, do not halt
or reverse the disease, and most have limited long-term
effectiveness [6]. The exception may be alemtuzumab for
which durable efficiency was reported in people with
RR-MS, including confirmed disability improvement
[7]. However, it is unknown how long the drug effective-
ness may last. Recently, ocrelizumab was approved as
the first drug for treatment of primary progressive MS
(PP-MS). Ocrelizumab is a humanized monoclonal anti-
body designed to selectively target CD20-positive B
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cells [8]. In this trial, a subset of people with PP-MS
receiving ocrelizumab showed a moderate degree of
slowing of disability accumulation compared to the pla-
cebo group [8]. In addition to suppression of ongoing
inflammation, remyelination is essential in MS to restore
saltatory conduction and axonal protection. Promotion of
remyelination and/or inhibition of demyelination is crit-
ical to prevent further neuronal loss and cognitive de-
cline observed in (progressive) MS [9]. Failure of
remyelination is one of the pathologic hallmarks of pro-
gressive MS.
The relation of aging with disease progression in MS
lends strong support to the hypothesis that progression
could potentially be induced by increased cellular senes-
cence in the CNS. Eliminating senescent cells delays
age-related dysfunction in mouse models [10, 11].
Therefore, the aim of this review is to explore whether
elimination of senescent cells could be a potential ther-
apeutic strategy for delaying progression of MS. When
cellular senescence is involved in MS disease progres-
sion, one could consider senolytics as a therapeutic
treatment to delay progression. First, cellular senescence
and its links with the progression of MS are discussed.
Second, the concept of senolytics and the potential use
of these drugs which specifically target senescent cells
as a treatment for progressive MS will be discussed.
Cellular senescence
Cellular senescence can be defined as an irreversible
arrest of the cell cycle coupled to stereotyped phenotyp-
ic changes to decrease the risk for malignant transfor-
mation of the cell [5]. The term senescence was first
introduced by Hayflick and Moorhead to describe the
phenomenon of irreversible growth arrest in serially
passaged human fibroblast culture, also known as repli-
cative senescence [12]. Now, it is known that the senes-
cence observed here was caused by telomere attrition
[12, 13]. Cellular senescence can also be induced by
many other stressors, including mitochondrial deteriora-
tion, oxidative stress, the expression of certain onco-
genes, DNA damage, chromatin disruption, spindle
stress, low expression of the mitotic spindle checkpoint
protein budding uninhibited by benzimidazole-related 1
(BubR1), and other insults [14]. Senescence can be
characterized by various markers, none of which is spe-
cific to senescent cells only and senescent cells may
express only some of the markers used to characterize
senescence. Major examples of these markers are G1
arrest (high expression of cell-cycle inhibitors p16Ink4a
and p21), high senescence-associated β-galactosidase
(SA-β-gal) activity, altered epigenome, oxidative stress,
DNA damage, and most importantly the senescence-
associated secretory phenotype (SASP) as detailed in
Box 1 [5, 15].
The secretory phenotype of senescent cells
One of the key characteristics that distinguish senescent
cells from other non-proliferating cells is the SASP
(Box 1). The SASP refers to the release of a wide array
of pro-inflammatory cytokines and chemokines, tissue-
damaging proteases, factors influencing stem- and pro-
genitor cell function, and haemostatic factors and growth
factors among other factors. The SASP factors can lead
to the development of local and systemic pathogenic
effects [5]. However, the influence of the SASP on the
microenvironment can also be beneficial during embry-
onic development or in an acute setting of wound
healing [18, 19].
The SASP factors can be subdivided into soluble signal-
ing factors, soluble shed receptors or ligands, non-protein
soluble factors, and insoluble factors (extracellular matrix
(ECM)/cytoskeleton/cell junctions). Soluble signaling fac-
tors are the major components of the SASP and can be
subdivided into interleukins, chemokines, other inflamma-
tory factors, growth factors, ox-redox factors, proteases
and their regulators, regulators of gene expression, and
miscellaneous.
The most prominent SASP cytokine is IL-6, which is
associated with senescence in various cell types such as
mouse and human keratinocytes, melanocytes, monocytes,
fibroblasts, and epithelial cells [20–22]. Senescent cells
can also influence the tissue microenvironment by the se-
cretion of non-protein soluble factors, such as reactive ox-
ygen species (ROS) [23–25]. Moreover, senescent cells
can have increased fibronectin expression as shown in pre-
maturely aging fibroblasts in Werner Syndrome [26, 27].
Fibronectin is a major ECM glycoprotein of connective
tissue, on cell surfaces and in plasma and other body fluids.
The glycoprotein can bind to integrins and ECM compo-
nents, such as collagen, and plays major roles in cell adhe-
sion, growth, migration, and differentiation.
Mechanisms of tissue deterioration by cellular senescence
Senescent cells are found in the affected tissues of patients with
age-related diseases and are thought to promote age-related
tissue dysfunction. The age-related diseases osteoarthritis, pul-
monary fibrosis, diabetes, atherosclerosis, and Alzheimer’s
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disease are already thought to be connected with cellular senes-
cence, suggesting that cellular senescence could be associated
with their genesis and progression [28]. The SASP can contrib-
ute to age-related inflammatory diseases by causing a paracrine
spread of cell dysfunction and tissue damage [29]. This can be
induced by disruption of the stem cell niche, and therefore
disruption of the tissue regeneration, by SASP factors [30,
31]. Furthermore, SASP proteases might also cause disruption
of the extracellular matrix by cleavage of components of the
tissue microenvironment [32]. Other SASP components, in-
cluding IL-6 and IL-8, may induce epithelial-mesenchymal
transition, stimulating tissue fibrosis and tumor metastasis
Box 1 - The senescence associated secretory phenotype (SASP).










CXCL8 / IL-8 ↑
CXCL1, 2, 3 / GRO α, β, γ ↑
CCL8 / MCP-2 ↑ [5]
CCL13 / MCP-4 ↑ [5]
CCL3 / MIP-1α ↑ [5]
CCL20 / MIP-3α ↑ [5]
CCL16 / HCC-4 ↑ [5]








EGF ↑ or × [5]
bFGF ↑ [5]
HGF ↑ [5]




SDF-1 ↑ or × [5]
PIGF ↑ [5]




TXNDC5 (ERP46) ↑ [17]
Proteases and regulators ref
MMP-1, -3, -10, -12, -13, -14 ↑ [5]
TIMP-1 ↓ or × [5]
TIMP-2 ↑ [5]
PAI-1, -2; tPA; uPA ↑ [5]
Cathepsin B ↑ [5]
Cathepsin D ↑ [17]
PSMB4 ↑ [17]
Regulators of gene expression
MVP ↑ [17]





Soluble or shed receptors or ligands
ICAM-1, -3 ↑ [5]
OPG ↑ [5]
sTNFRI ↑ [5]







Nitric oxide ↑ [5]





Filamin B ↑ [112]
Tubulin alpha 1C chain ↑ [112]
Tubulin beta chain ↑ [112]
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[33, 34]. Senescent cells may also play a role in chronic
tissue inflammation associated with the development of
age-related diseases. Senescent cells accumulate in tissues
manifesting age-related inflammatory pathologies and
promote this inflammation through pro-inflammatory
SASP factors. SASP factors IL-1β, TGFβ, and certain
chemokine ligands may induce senescence in neighboring
cells, sustaining and also exacerbating the previously
mentioned mechanisms of tissue deterioration by increas-
ing the number of senescent cells (Fig. 1) [35].
Aging and cellular senescence in MS
MS is a chronic, often progressive, demyelinating disease of
the CNS white and gray matter. Despite the fact that the dis-
ease course and symptomatology of MS are very heteroge-
neous from person to person, several disease subtypes can
be recognized. The most common subtype is RR-MS, charac-
terized by acute episodes of neurological deficits followed by
periods of recovery. Aging seems to be a significant factor in
MS disease progression. Those diagnosed with RR-MS have a
50% chance to transit to secondary progressive MS (SP-MS)
within 10 years, and a 90% chance within 25 years. SP-MS is
characterized by progressive decline, with or without relapses.
In approximately 10–20% of the individuals that develop MS,
the disease from the start slowly progresses over time and
there are no (or occasionally minor) signs of remission after
onset of the initial symptoms. This subtype is referred to as
PP-MS. The histopathological hallmarks of MS are multifocal
lesions with demyelination, oligodendrocyte death, axonal
loss, and accumulation of blood-borne immune cells. The
RR-MS course is characterized by inflammation followed by
demyelination, adaptive immunity, activated astrocytes, dis-
turbed blood-brain barrier (BBB) function, and (incomplete)
remyelination. Conversely, SP-MS course is characterized by
axonal degeneration, innate immunity, reactive astrocytes
(gliosis), closed BBB, and hardly any remyelination [36].
The age distribution of MS is shifting to older age groups,
from a peak prevalence of 50–54 years in 1984 to 55–59 years
in 2004. People over the age of 65 who have been diagnosed
with MS are more likely to have PP-MS or have an earlier
transition to a SP-MS course, compared to younger people
(under 65) [3, 37, 38]. MS disease progression can occur at
varying rates between individuals, possibly due to varying
underlying biological mechanisms often related to genetic
Fig. 1 Mechanisms of tissue deterioration by cellular senescence.
Cellular senescence can contribute to age-related tissue dysfunction by
at least the following general mechanisms: paracrine senescence,
stimulation of the infiltration of immune cells, disruption of the extracel-
lular matrix, and by induction of epithelial to mesenchymal transition
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and/or environmental factors [39, 40]. Importantly, increasing
age has been shown to be a strong predictor for progression in
MS, independent of the subtype and age of onset [38].
Mechanisms of senescence-related MS disease
progression
It was recently shown that chronic demyelination observed in
a cuprizone mouse model is associated with accelerated glial
cell senescence in demyelinated lesions [41]. Moreover, in-
flammation, ROS, and fibronectin accumulation, which are
also part of the SASP, are thought to play a role in the patho-
genesis of MS. This suggests that the age-related disease pro-
gression observed in MS could potentially be functionally
linked to cellular senescence. Here, we describe the mecha-
nisms by which different senescent cell types could influence
MS disease progression. An overview of these mechanisms is
shown in Fig. 2.
Senescence of microglia and macrophages
The aging CNS shows decreased capacity for tissue repair,
which could contribute to the progression of MS [43, 44].
One potential mechanism for this decreased repair response
is immune-aging of microglia and macrophages [45].
Microglia are the resident immune cells of the CNS providing
surveillance during homeostasis and against a wide variety of
insults. This surveillance state is maintained by soluble mole-
cules expressed in the CNS, such as transforming growth fac-
tor β, and ligands expressed on the surface of neurons, astro-
cytes, and oligodendrocytes [46]. Microglia are activated in
MS, possibly promoting the infiltration of monocytes and
lymphocytes into the CNS, changes in BBB integrity and
secretion of inflammatory cytokines. Finally, this could pro-
mote to neuronal damage and death. Microglia also reactivate
T cells, which enter the CNS from the periphery [47].
One of the main pathological differences between progres-
sive and non-progressive MS is remyelination failure.
Remyelination is essential for restoration of saltatory conduc-
tion and axonal protection [48]. Remyelination does occur in
the early stages of the disease, but it declines as the disease
progresses [44]. The expression of genes involved in the ret-
inoid X receptor pathway is decreased in aging myelin-
phagocytosing macrophages [49]. In addition, disruption of
retinoid X receptor function in young macrophages results in
aging-related decrease in myelin debris uptake [49].
Fig. 2 Potential mechanisms
contributing to MS disease
progression by senescence of
different cell types. Different cell
types could potentially become
senescent and contribute to MS
disease progression. The putative
mechanisms are shown in the red
and green boxes. Green boxes
indicate that senescence of these
cell types has been observed in
vivo; red boxes indicate that
senescence of these cell types has
not yet been observed in vivo.
Free-ware images of microglia,
oligodendrocyte, astrocyte, and
neuron are based on Bcells of the
CNS^ [42]
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Furthermore, retinoid X receptor agonists were able to partial-
ly restore myelin debris clearance. These results suggest that
the retinoid X receptor pathway, which shows decreased ac-
tivity in aging macrophages, plays a key role in remyelination
due to its influence on myelin debris clearance [49, 50].
Moreover, aging microglia show decreased motility and cel-
lular migration in response to tissue injury compared to young
microglia [51]. Also, macrophages exhibit a decreased ability
to produce a pro-inflammatory response, while microglia
show an increased ability to produce a pro-inflammatory re-
sponse [46, 52]. This increased microglial response is referred
to as microglial priming and might lead to increased neuronal
loss and accelerated progression in MS [53]. The age-
associated delay in remyelination efficiency has been associ-
ated with reduction in macrophage/microglia recruitment in a
toxin-induced demyelinating model [54]. The age-associated
delay in remyelation can be explained by the decreased ability
to resolve the inflammatory response initiated after myelin
damage [55]. The breakdown of myelin results in the release
of large amounts of cholesterol from the myelin [55].
Ingestion of myelin debris by macrophages induces an anti-
inflammatory program [56]. Very recent mouse studies demon-
strate large amounts of cholesterol overwhelm the efflux capacity
of aged phagocytes, resulting in a phase transition of cholesterol
into crystals and thereby inducing lysosomal rupture and NOD-
like receptor family pyrin domain-containing protein 3 (NLRP3)
inflammasome stimulation [55]. Thus, age-related defective cho-
lesterol clearance limits remyelination.
Microglia and macrophages play a major role in the clear-
ance of myelin debris and the recruitment of oligodendrocyte
precursor cells (OPC) to the lesion site [57]. Aged microglia
and macrophages show decreased phagocytosis and chemo-
taxis [58]. Decreased chemotaxis could result in impairment
of the recruitment of endogenous OPC. The impairment in
phagocytosis could result in impaired clearance of myelin
debris and subsequent arrest of the differentiation of OPC
[50]. The exact role of senescent microglia and macrophages
in these processes is not known. There is some evidence
supporting the induction of cellular senescence in microglia.
In vitro experiments with the microglia-like cell line BV2
showed that these cells go into senescence after multiple in-
flammatory challenges indicating that this might also be pos-
sible in vivo [59]. The actual existence of senescent microglia
and macrophages in vivo is yet to be confirmed.
Senescence of T cells
Besides microglia and macrophages, senescent brain-
infiltrating T cells are likely critical in the progression of
MS. Unlike the previously mentioned cell types, it has been
shown that T cells can become senescent in vivo, as reflected
by increased expression of CD57 and killer cell lectin like
receptor G1 (KLRG1) on CD8+ T cells from aged individuals
[60]. The numbers of senescent CD8+ T cells are increased in
the aging brain and their increased pro-inflammatory cytokine
production could aggravate the neuro-inflammation. This
could worsen the cognitive function and drive progression of
MS, since cytotoxic CD8+ T cells can drive neuronal damage
[61]. CD8+ Tcells are found abundantly inMS lesions and the
number of cells correlates with the axonal damage rate in the
lesions [62, 63]. Furthermore, all CNS cell types show in-
creased MHC class I expression in the lesions [64]. This sug-
gests that senescent, dysfunctional CD8+ T cells can target
glial cells and neurons by direct recognition of the cell and/
or myelin sheath via MHC class I or by excessive cytokine
production, and therefore they likely play a role in the pro-
gression of MS.
Senescence of astrocytes
Aging can also influence the function of astrocytes, the most
abundant cell type in the brain. Senescence of astrocytes may
lead to changes in many astrocyte-regulated processes among
which synaptic plasticity, metabolic balance, and BBB perme-
ability. Senescent astrocytes have an increased expression of
glial fibrillary acidic protein (GFAP) and vimentin filaments,
increased expression of pro-inflammatory cytokines, and in-
creased accumulation of proteotoxic aggregates [65]. GFAP
levels in CSF of rodents and humans correlate with age and
disease progression inMS, suggesting that senescent astrocytes
might also contribute to disease progression [66, 67]. Senescent
astrocytes could have a decreased capacity to support
neurogenesis and to provide neuronal protection. GFAP/
vimentin knockout mice have an increased cellular proliferation
and neurogenesis [68]. Moreover, astrocytes without GFAP
have an increased capacity to provide neuronal survival and
neurite outgrowth compared to wild-type astrocytes [69].
Furthermore, senescent astrocytes have an increased expression
of pro-inflammatory cytokines, such as IL-6, TNF-α, IL-1β,
and prostaglandins, which negatively affect BBB function [70].
Astrocytes also have an important role in the neuron-glial
crosstalk; they maintain metabolic and ion homeostasis of
neurons, modulate synaptic transmission via glutamate, and
they modulate neuronal activity [71, 72]. Therefore, senes-
cence of astrocytes might promote neuronal dysfunction and
degeneration, contributing to the progression of MS.
Glial scar formation, also referred to as gliosis, is effected
by reactive astrocytes and it develops as the disease progresses
[73]. Therefore, this process could be related to cellular senes-
cence of astrocytes and other CNS cell types. Gliosis can have
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both beneficial and detrimental effects. The supposed benefi-
cial effect is to physically isolate the damaged CNS areas to
prevent spread of tissue destruction. Nonetheless, this process
also has detrimental effects since it inhibits remyelination and
axonal regeneration. The overproduction of FGF-2 and
hyaluronan by astrocytes inhibits OPC differentiation and
therefore remyelination. Also, the release of chondroitin sul-
phate proteoglycans (CSGP), ephrins (EPH), and their recep-
tors, as well as myelin-associated inhibitors (MAI), inhibits
remyelination and suppresses axonal growth [73].
Nonetheless, the role of senescent astrocytes in MS is not
well-studied and the previously mentioned mechanisms by
which senescent astrocytes could influence MS disease pro-
gression are not yet confirmed. Interestingly, it has been
shown very recently that post-mortem Parkinson’s disease
(PD) brain samples show increased astrocytic senescence
and that astrocytic senescence could be induced by the herbi-
cide paraquat both in vitro and in vivo [74]. Moreover, clear-
ance of senescent cells by using a special PD mouse model
that allows selective depletion without apparent off-target ef-
fects mitigates paraquat-induced neuropathology. Therefore,
accumulation of senescent astrocytes might contribute to de-
velopment of sporadic PD [74].
Senescence of endothelial cells
The senescence of endothelial cells lining the surface of blood
vessels in the CNS is thought to contribute to disruption of
BBB function. Impaired barrier integrity was observed in an
in vitro BBB model, composed of senescent endothelial cells,
pericytes, and astrocytes [75]. In vivo experiments with
BubR1H/H progeria mice showed impaired BBB integrity
and increased senescence of endothelial cells and pericytes.
Moreover, oxidative stress can induce endothelial senescence
possibly by downregulation of sirtuin 6 (Sirt6), a regulator of
endothelial cell senescence [76]. Radiation-induced senes-
cence of endothelial cells results in the downregulation of a
disintegrin and metalloprotease (ADAM) 10 [77]. This pro-
tein is the alpha-secretase that cleaves amyloid precursor pro-
tein (APP). This mechanism is considered important in
preventing the formation of amyloid beta in Alzheimer’s dis-
ease (AD). In addition, ADAM10 can cleave many more pro-
teins, including TNF-α and E-cadherin, and thereby promot-
ing inflammation and affecting epithelial cell-cell adhesion
[78, 79]. ADAM10 can also cleave the extracellular domain
of the B cell-activating factor (BAFF)—a proliferation-
inducing ligand (APRIL)—receptor transmembrane activator
and calcium modulator and cyclophilin ligand interactor
(TACI), releasing soluble TACI (sTACI) [80]. The BAFF-
APRIL system is involved in the regulation of B cell
homeostasis. sTACI levels are increased in CSF of MS pa-
tients and are thought to induce B cell accumulation and acti-
vation [80].
Senescence of pericytes and perivascular fibroblast-like cells
In addition to endothelial cells and astrocytes, pericytes con-
tribute to the BBB. However, the physiological role of these
cells is not well established [81]. Pericytes are essential in
maintaining the BBB during brain aging and loss of pericytes
leads to reduction in brain microcirculation and BBB break-
down [82]. Senescence of these cells might lead to impairment
of their normal function and therefore contribution to neuro-
inflammation and neurodegeneration. Recently, perivascular
fibroblast-like cells were identified. These cells are located
between the vessel wall and the astrocytic end-feet, and show
resemblance to lung fibroblasts combined with epithelial
(Lama1), endothelial (Cdh5), and mesothelial (Efemp1)
markers [83]. Perivascular fibroblast-like cells could be the
origin of pathological fibroblasts [84]. These pathological fi-
broblast cells are activated in experimental models of neuro-
inflammation such as EAE and infection with the neurotropic
hepatitis virus, as evidenced by rapid production of chemo-
kine receptor 7 ligands [85, 86]. Fibroblast activation during
chronic CNS inflammation contributes to the inflammatory
response by recruitment of immune cells at sites of inflamma-
tion and secretion pro-inflammatory cytokines and survival
factors to retain activated immune cells [87]. Senescence of
vascular cells contributes to BBB disruption, as shown by
impaired barrier integrity and tight junction structure in an in
vitro BBB model constructed with senescent endothelial cells
and pericytes [75].
Senescence of oligodendrocytes
OPC migrate toward the injured axon site after signaling by
microglia or astrocytes. At the site, theymust differentiate into
mature oligodendrocytes (OLG) to be able to remyelinate the
axon. Most OPC, which have a crucial role in remyelination,
can avoid replicative senescence [88]. Nonetheless, there is
evidence that OPC can become senescent [89]. Senescence
of OLG might decrease remyelination capacity of
demyelinated axons, which could lead to decrease in signaling
ability and loss of protection of neurons and eventually neu-
ronal cell death in MS.
Senescence of neurons
Senescence of neural stem cells could reduce neuronal
neurogenesis, which can also contribute to the aging-
associated progression of MS [90]. The expression of
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transcriptional regulator Hmga2 (high-mobility group AT-
hook 2) in neural stem cells declines with age, resulting in
an increased expression of p16Ink4a and p19Arf which can both
induce cellular senescence [91].
SA-β-gal is commonly used biomarker of cell senes-
cence and is found to be increased in the hippocampus of
24-month-old mice [92]. However, relatively high expres-
sion of SA-β-gal activity was also found in the hippocam-
pus of 3-month-old mice, suggesting that SA-β-gal in
neurons is not a unique marker of neuronal senescence
[92]. DNA damage does not increase the number of
SA-β-gal-positive neurons [92]. Moreover, sustained
DNA damage of post-mitotic neurons can lead to the de-
velopment of a p21-dependent senescent phenotype [93].
However, p21 expression did not show days-in-culture-
dependent changes in cortical neurons [92]. These find-
ings suggest that cell-cycle regulators associated with cel-
lular senescence may not be relevant markers of senes-
cence in post-mitotic neurons. Alternatively, repressor el-
ement 1-silencing transcription factor (REST) could pos-
sibly be used as a specific marker of neuronal aging in
vitro [92]. Despite the controversy about senescence
markers for neurons, overall, these results suggest that
neurons indeed can become senescent. Senescence then
can have direct effects on neuronal function and possibly
MS disease progression.
In AD models, neuronal senescence is thought to be trig-
gered by amyloid β and tau hyper-phosphorylation/accumu-
lation. Neuronal senescence eventually might cause chronic
neurodegeneration and cognitive impairment [94, 95].
Role of the SASP
Increased levels of pro-inflammatory molecules, secreted
by senescent cells, can promote inflammation and might
promote progression of MS. SASP factors secreted by se-
nescent cells are also able to influence the extracellular
matrix. The extracellular matrix is one of the factors regu-
lating migration and proliferation of oligodendrocyte pro-
genitor cells and their differentiation. For example, fibro-
nectin promotes proliferation and reduces myelin-like
membrane formation [96]. Fibronectin is upregulated in
MS lesions and CNS parenchyma, affecting remyelination
[97, 98]. Astrocytes generate fibronectin aggregates upon
engagement with inflammatory mediators [99]. The pro-
inflammatory factors of the SASP could therefore induce
the generation of fibronectin aggregates. Senescent endo-
thelial cells and fibroblasts have increased fibronectin ex-
pression [27]. The age-related increase of senescent cells in
MS could therefore contribute to the increased fibronectin
expression and progression of MS.
Targeting senescent cells with senolytic drugs
Potential therapeutic strategies to prevent the deleterious
effects caused by senescent cells are based on preventing
formation of senescent cells, removal of senescent cells,
and targeting the effects of senescent cells. Preventing for-
mation of senescent cells requires interference with path-
ways leading to senescence. In addition, cellular senes-
cence is a defense mechanism against cancer and therefore
long-term interference with these pathways is likely to pro-
mote cancer [100]. Preventing or ameliorating the effects
of the SASP could also be a potential therapeutic approach
to decrease inflammation and cancer risk. However, this
also inhibits the beneficial arm of the SASP. Elimination
of senescent cells, on the other hand, has a larger potential
to delay age-related degenerative pathologies [10]. Cancer
risk would be reduced by activation of the tumor-
suppressive pathway, leading to cellular senescence and,
by removal of senescent cells, prevent malignant transfor-
mation of neighboring cells [10, 101]. Furthermore, elim-
ination of senescent cells can be done intermittently which
does not affect the formation of new senescent cells for
purposes such as wound healing [19].
Different agents, including small molecules, peptides,
and antibodies, called senolytics, are being developed to
specifically remove senescent cells [102]. Senescent cells
are resistant to apoptosis despite their own pro-apoptotic
SASP factor release. Senolytics are directed against the
pro-survival pathways of senescent cells, also referred to
as senescent cell anti-apoptotic pathways (SCAP). These
SCAP, responsible for the survival of senescent cells,
were identified as the Achilles’ heel of senescent cells
[103]. Both cellular senescence and mitochondrial dys-
function are the hallmarks of aging and are closely
interlinked; upregulation of the SCAP is related to
senescence-associated mitochondrial dysfunction
(SAMD) and, at the same time, SAMD also drives and
maintains cellular senescence [4, 104].
Thus far, six different SCAP are known: Bcl-2/Bcl-XL
family, PI3K/Akt/ROS protective/metabolic, p53/p21/
serpine, ephrins/dependence receptors/tyrosine kinases,
HIF-1α, and heat shock protein 90 (HSP-90) [103, 105].
A number of senolytic drugs are developed based on inter-
ference with these SCAP. Current senolytics are listed in
Box 2. Senolytics can selectively induce apoptosis in se-
nescent cells and can potentially be used in multiple age-
related phenotypes. Recently, it has been shown that inter-
mittent oral administration of the senolytic cocktail of
dasatinib and quercetin decreased the number of naturally
occurring senescent cells and alleviated physical dysfunc-
tion and increased survival in old mice [106].
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Effects of cellular senescence in MS
There is initial evidence from animal models supporting the
role of cellular senescence in the processes underlying disease
progression in MS, for instance the increased cellular senes-
cence observed in the cuprizonemodel [41]. This is a model in
which young adult mice are fed with the copper chelator
cuprizone, resulting in demyelination. This demyelination is
caused by apoptotic cell death of oligodendrocytes, due to a
disturbance in energy metabolism. This model has been asso-
ciated with microglia and macrophage responses, but not with
Tcell activation and their recruitment into to the CNS [114]. In
this model, they observed a 2.9-fold increase in senescent glial
cell load in the corpus callosum as evidenced by SA-β-gal
histochemistry at week 16.
Also in MS, there is some evidence for premature
immunosenescence. One of the characteristics of
immunosenescence is the expansion of CD4+ CD28− T cells.
These cells accumulate in MS lesions [115–117]. It has also
been suggested that senescent CD8+ T cells could contribute
to disease progression but the evidence is less clear [118].
The occurrence of other effects of cellular senescence in
MS has only been hypothesized and has not been confirmed
yet. For example, the chronic secretion of ROS generated by
senescent cells and inflammatory cells as they attack myelin
might cause a spread of demyelination. This can at least partly
explain why cortical demyelination is found in patients suffer-
ing from progressive MS, but not in acute MS [119]. Another
SASP factor that could contribute to MS disease progression
is the ECM glycoprotein fibronectin. Fibronectin contributes
to remyelination failure and increased fibronectin expression
by senescent cells and can therefore enhance this phenomenon
[97, 98]. Furthermore, the pro-inflammatory cytokines secret-
ed by senescent cells can directly influence the surrounding
brain tissue, which might drive neurodegeneration. Also, in-
flammatory mediators are thought to induce increased fibro-
nectin expression by astrocytes [99]. Moreover, the age-
related iron accumulation observed in progressiveMS patients
is likely to be a consequence of cellular senescence [36, 120].
In conclusion, senescence of cells present in the CNS in MS
could contribute to MS disease progression, but more mecha-
nistic research is necessary to support this hypothesis.
Box 2 – Current senolytics and their targeted senescent cell anti-apoptotic pathway (SCAP)
Senolytic SCAP ref
Desatinib (D) Ephrins/dependence receptors/tyrosine kinases
(Ephrin receptors)
[103]






Navitoclax (ABT263) Bcl-2 family [108]
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* Quercetin was recently reported to not be effective as a senolytic for primary adult endothelial cells [120]
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Conclusions and future outlook
From our review we conclude that there is ample evidence
to warrant further studies into the possible link between
cellular senescence and progression of MS. Future in vitro
studies on the different cell types present in the CNS can
elucidate the mechanisms through which these cells be-
come senescent and if the senescent phenotype alters their
role in important processes such as myelin debris clearance,
remyelination, and axonal protection. The results of these
studies can be used to guide a focused search for senescent
cells in MS lesions in post-mortem brain tissue from differ-
ent MS subtypes. This will further strengthen the link be-
tween cellular senescence and disease progression in MS.
The final preclinical step would be to test senolytic treat-
ment protocols using in vitro (e.g., brain-on-a-chip) and in
vivo (EAE, cuprizone) models of demyelination and MS.
Adding senolytic treatment to effective immunomodulato-
ry and remyelination promoting therapy could result in a treat-
ment strategy which can limit further disability accrual in pa-
tients withMS and thus have great impact on the prognosis for
people with MS.
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